Ventyx unveils positive PhII ulcerative colitis data but stock is down 20% due to competitive spacenews2023-10-10T11:33:02+00:00October 10th, 2023|Endpoints News|
Immunic releases PhII biomarker data in progressive multiple sclerosisnews2023-10-10T11:16:07+00:00October 10th, 2023|Endpoints News|
Exclusive: Andreessen Horowitz-backed Mana.bio launches for AI-designed lipid nanoparticlesnews2023-10-10T11:00:42+00:00October 10th, 2023|Endpoints News|
Novo Nordisk lawsuit over compounded semaglutide is dismissed, but company plans to file againnews2023-10-09T19:09:31+00:00October 9th, 2023|Endpoints News|
Setting up a showdown with Boehringer, Pfizer scores interchangeability tag for its Humira biosimilarnews2023-10-09T19:03:37+00:00October 9th, 2023|Endpoints News|
AnaptysBio touts PhIII win in a rare form of psoriasis. But it doesn’t plan on keeping the drugnews2023-10-09T19:00:32+00:00October 9th, 2023|Endpoints News|
Astellas proposes ‘More Not Flashes’ in first branded ad for Veozah menopause treatmentnews2023-10-09T18:56:38+00:00October 9th, 2023|Endpoints News|
FDA submits more questions to Oncopeptides over Pepaxto withdrawalnews2023-10-09T18:28:48+00:00October 9th, 2023|Endpoints News|
Cancer centers still under generic drug supply constraints, subsequent price hikesnews2023-10-09T17:46:34+00:00October 9th, 2023|Endpoints News|
California Gov. Gavin Newsom vetoes bill to cap insulin prices at $35 per monthnews2023-10-09T16:59:14+00:00October 9th, 2023|Endpoints News|
